vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Skyward Specialty Insurance Group, Inc. (SKWD). Click either name above to swap in a different company.
Skyward Specialty Insurance Group, Inc. is the larger business by last-quarter revenue ($385.6M vs $247.1M, roughly 1.6× ANI PHARMACEUTICALS INC). Skyward Specialty Insurance Group, Inc. runs the higher net margin — 11.2% vs 11.1%, a 0.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 26.7%). Skyward Specialty Insurance Group, Inc. produced more free cash flow last quarter ($402.6M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 20.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Skyward Specialty Insurance Group, Inc. is a specialty property and casualty insurance provider offering tailored coverage solutions including commercial auto, general liability, professional indemnity, and specialty property policies. It primarily serves small-to-medium enterprises and niche industry segments across the United States, focusing on underwriting complex, hard-to-place risks for underserved client groups.
ANIP vs SKWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $385.6M |
| Net Profit | $27.5M | $43.2M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 14.2% |
| Net Margin | 11.1% | 11.2% |
| Revenue YoY | 29.6% | 26.7% |
| Net Profit YoY | 367.5% | 200.1% |
| EPS (diluted) | $1.14 | $1.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $385.6M | ||
| Q3 25 | $227.8M | $382.5M | ||
| Q2 25 | $211.4M | $319.9M | ||
| Q1 25 | $197.1M | $328.5M | ||
| Q4 24 | $190.6M | $304.4M | ||
| Q3 24 | $148.3M | $300.9M | ||
| Q2 24 | $138.0M | $279.9M | ||
| Q1 24 | $137.4M | $265.0M |
| Q4 25 | $27.5M | $43.2M | ||
| Q3 25 | $26.6M | $45.9M | ||
| Q2 25 | $8.5M | $38.8M | ||
| Q1 25 | $15.7M | $42.1M | ||
| Q4 24 | $-10.3M | $14.4M | ||
| Q3 24 | $-24.2M | $36.7M | ||
| Q2 24 | $-2.3M | $31.0M | ||
| Q1 24 | $18.2M | $36.8M |
| Q4 25 | 14.1% | 14.2% | ||
| Q3 25 | 15.9% | 15.8% | ||
| Q2 25 | 6.6% | 15.6% | ||
| Q1 25 | 13.3% | 15.7% | ||
| Q4 24 | -2.3% | 6.1% | ||
| Q3 24 | -13.8% | 15.6% | ||
| Q2 24 | 3.7% | 14.4% | ||
| Q1 24 | 14.8% | 17.7% |
| Q4 25 | 11.1% | 11.2% | ||
| Q3 25 | 11.7% | 12.0% | ||
| Q2 25 | 4.0% | 12.1% | ||
| Q1 25 | 8.0% | 12.8% | ||
| Q4 24 | -5.4% | 4.7% | ||
| Q3 24 | -16.3% | 12.2% | ||
| Q2 24 | -1.7% | 11.1% | ||
| Q1 24 | 13.2% | 13.9% |
| Q4 25 | $1.14 | $1.03 | ||
| Q3 25 | $1.13 | $1.10 | ||
| Q2 25 | $0.36 | $0.93 | ||
| Q1 25 | $0.69 | $1.01 | ||
| Q4 24 | $-0.45 | $0.33 | ||
| Q3 24 | $-1.27 | $0.89 | ||
| Q2 24 | $-0.14 | $0.75 | ||
| Q1 24 | $0.82 | $0.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $168.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.0B |
| Total Assets | $1.4B | $4.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $168.5M | ||
| Q3 25 | $262.6M | $160.1M | ||
| Q2 25 | $217.8M | $136.6M | ||
| Q1 25 | $149.8M | $112.9M | ||
| Q4 24 | $144.9M | $121.6M | ||
| Q3 24 | $145.0M | $105.6M | ||
| Q2 24 | $240.1M | $73.0M | ||
| Q1 24 | $228.6M | $85.1M |
| Q4 25 | $540.7M | $1.0B | ||
| Q3 25 | $505.8M | $961.4M | ||
| Q2 25 | $436.8M | $899.9M | ||
| Q1 25 | $418.6M | $850.7M | ||
| Q4 24 | $403.7M | $794.0M | ||
| Q3 24 | $405.9M | $797.5M | ||
| Q2 24 | $455.8M | $723.6M | ||
| Q1 24 | $452.0M | $692.3M |
| Q4 25 | $1.4B | $4.8B | ||
| Q3 25 | $1.4B | $4.6B | ||
| Q2 25 | $1.3B | $4.3B | ||
| Q1 25 | $1.3B | $4.0B | ||
| Q4 24 | $1.3B | $3.7B | ||
| Q3 24 | $1.3B | $3.6B | ||
| Q2 24 | $920.8M | $3.4B | ||
| Q1 24 | $914.5M | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $408.1M |
| Free Cash FlowOCF − Capex | $29.1M | $402.6M |
| FCF MarginFCF / Revenue | 11.8% | 104.4% |
| Capex IntensityCapex / Revenue | 0.5% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.10× | 9.44× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $755.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $408.1M | ||
| Q3 25 | $44.1M | $171.4M | ||
| Q2 25 | $75.8M | $88.2M | ||
| Q1 25 | $35.0M | $96.8M | ||
| Q4 24 | $15.9M | $305.1M | ||
| Q3 24 | $12.5M | $168.0M | ||
| Q2 24 | $17.4M | $21.0M | ||
| Q1 24 | $18.3M | $94.3M |
| Q4 25 | $29.1M | $402.6M | ||
| Q3 25 | $38.0M | $168.9M | ||
| Q2 25 | $71.8M | $87.1M | ||
| Q1 25 | $32.5M | $96.6M | ||
| Q4 24 | $13.5M | $300.9M | ||
| Q3 24 | $7.7M | $167.6M | ||
| Q2 24 | $13.0M | $18.4M | ||
| Q1 24 | $13.7M | $94.0M |
| Q4 25 | 11.8% | 104.4% | ||
| Q3 25 | 16.7% | 44.2% | ||
| Q2 25 | 34.0% | 27.2% | ||
| Q1 25 | 16.5% | 29.4% | ||
| Q4 24 | 7.1% | 98.8% | ||
| Q3 24 | 5.2% | 55.7% | ||
| Q2 24 | 9.4% | 6.6% | ||
| Q1 24 | 10.0% | 35.5% |
| Q4 25 | 0.5% | 1.4% | ||
| Q3 25 | 2.7% | 0.6% | ||
| Q2 25 | 1.9% | 0.3% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.3% | 1.4% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.9% | ||
| Q1 24 | 3.3% | 0.1% |
| Q4 25 | 1.10× | 9.44× | ||
| Q3 25 | 1.66× | 3.73× | ||
| Q2 25 | 8.87× | 2.27× | ||
| Q1 25 | 2.23× | 2.30× | ||
| Q4 24 | — | 21.18× | ||
| Q3 24 | — | 4.58× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | 1.00× | 2.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SKWD
Segment breakdown not available.
